S&P 500   4,306.51 (+0.22%)
DOW   34,154.08 (+0.71%)
QQQ   331.96 (-0.33%)
AAPL   172.95 (-0.14%)
MSFT   292.51 (-0.33%)
META   179.03 (-1.03%)
GOOGL   121.63 (-0.37%)
AMZN   143.71 (+0.37%)
TSLA   927.46 (-0.05%)
NVDA   188.68 (-0.86%)
NIO   20.86 (-2.07%)
BABA   92.64 (-1.66%)
AMD   99.75 (-1.25%)
MU   64.11 (-0.91%)
T   18.66 (+1.47%)
CGC   3.66 (-4.19%)
F   16.42 (+0.61%)
GE   79.93 (+0.15%)
DIS   125.19 (+0.75%)
AMC   24.80 (+2.44%)
PYPL   102.10 (+0.58%)
PFE   49.74 (-0.02%)
NFLX   247.36 (-0.70%)
S&P 500   4,306.51 (+0.22%)
DOW   34,154.08 (+0.71%)
QQQ   331.96 (-0.33%)
AAPL   172.95 (-0.14%)
MSFT   292.51 (-0.33%)
META   179.03 (-1.03%)
GOOGL   121.63 (-0.37%)
AMZN   143.71 (+0.37%)
TSLA   927.46 (-0.05%)
NVDA   188.68 (-0.86%)
NIO   20.86 (-2.07%)
BABA   92.64 (-1.66%)
AMD   99.75 (-1.25%)
MU   64.11 (-0.91%)
T   18.66 (+1.47%)
CGC   3.66 (-4.19%)
F   16.42 (+0.61%)
GE   79.93 (+0.15%)
DIS   125.19 (+0.75%)
AMC   24.80 (+2.44%)
PYPL   102.10 (+0.58%)
PFE   49.74 (-0.02%)
NFLX   247.36 (-0.70%)
S&P 500   4,306.51 (+0.22%)
DOW   34,154.08 (+0.71%)
QQQ   331.96 (-0.33%)
AAPL   172.95 (-0.14%)
MSFT   292.51 (-0.33%)
META   179.03 (-1.03%)
GOOGL   121.63 (-0.37%)
AMZN   143.71 (+0.37%)
TSLA   927.46 (-0.05%)
NVDA   188.68 (-0.86%)
NIO   20.86 (-2.07%)
BABA   92.64 (-1.66%)
AMD   99.75 (-1.25%)
MU   64.11 (-0.91%)
T   18.66 (+1.47%)
CGC   3.66 (-4.19%)
F   16.42 (+0.61%)
GE   79.93 (+0.15%)
DIS   125.19 (+0.75%)
AMC   24.80 (+2.44%)
PYPL   102.10 (+0.58%)
PFE   49.74 (-0.02%)
NFLX   247.36 (-0.70%)
S&P 500   4,306.51 (+0.22%)
DOW   34,154.08 (+0.71%)
QQQ   331.96 (-0.33%)
AAPL   172.95 (-0.14%)
MSFT   292.51 (-0.33%)
META   179.03 (-1.03%)
GOOGL   121.63 (-0.37%)
AMZN   143.71 (+0.37%)
TSLA   927.46 (-0.05%)
NVDA   188.68 (-0.86%)
NIO   20.86 (-2.07%)
BABA   92.64 (-1.66%)
AMD   99.75 (-1.25%)
MU   64.11 (-0.91%)
T   18.66 (+1.47%)
CGC   3.66 (-4.19%)
F   16.42 (+0.61%)
GE   79.93 (+0.15%)
DIS   125.19 (+0.75%)
AMC   24.80 (+2.44%)
PYPL   102.10 (+0.58%)
PFE   49.74 (-0.02%)
NFLX   247.36 (-0.70%)
OTCMKTS:OPHLF

Ono Pharmaceutical - OPHLF Stock Forecast, Price & News

$27.76
0.00 (0.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.76
$27.76
50-Day Range
$24.90
$27.76
52-Week Range
$20.57
$27.76
Volume
N/A
Average Volume
1,494 shs
Market Capitalization
$14.27 billion
P/E Ratio
19.28
Dividend Yield
N/A
Price Target
N/A
OPHLF stock logo

About Ono Pharmaceutical (OTCMKTS:OPHLF) Stock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

OPHLF Stock News Headlines

Ono Pharmaceutical Co. Ltd (OPHLF)
Here's what Wall Street expects from Ono Pharmaceutical's earnings
Here's what to expect from Ono Pharmaceutical's earnings
News for Ono Pharmaceutical
Fate Therapeutics Jumped On Supportive Trial Data
Gilead's Cancer Follies
Ono Pharmaceutical Co., Ltd. (OPHLF)
Ono Pharmaceutical Co Ltd (Japan) (OPHLF)
See More Headlines
Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

OPHLF Company Calendar

Today
8/16/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:OPHLF
Employees
3,687
Year Founded
N/A

Profitability

Net Income
$716.61 million
Pretax Margin
29.06%

Debt

Sales & Book Value

Annual Sales
$3.22 billion
Cash Flow
$1.70 per share
Book Value
$11.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$14.27 billion
Optionable
Not Optionable
Beta
0.42

Key Executives

  • Mr. Gyo Sagara (Age 64)
    CEO, Pres & Representative Director
  • Mr. Shozo Matsuoka Ph.D.
    Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
  • Yukio Tani
    Corp. Exec. Officer & Head of Corp. Communications
  • Katsuji Teranishi
    Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.
  • Mr. Isao Ono (Age 63)
    Exec. Officer, Director of Corp. Research & Director
  • Mr. Hiroshi Ichikawa
    Corp. Officer & Sr. Director of Medical External Affairs
  • Mr. Toichi Takino Ph.D. (Age 54)
    Sr. Exec. Officer, Exec. Director of Discovery & Research and Director
  • Mr. Toshihiro Tsujinaka (Age 58)
    Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
  • Hiromu Habashita Ph.D.
    Corp. Officer and Deputy Exec. Director of Discovery & Research Division
  • Kiyoaki Idemitsu (Age 58)
    Exec. Officer, Exec. Director of Clinical Devel. & Director













OPHLF Stock - Frequently Asked Questions

How have OPHLF shares performed in 2022?

Ono Pharmaceutical's stock was trading at $25.0350 on January 1st, 2022. Since then, OPHLF stock has increased by 10.9% and is now trading at $27.76.
View the best growth stocks for 2022 here
.

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a increase in short interest in July. As of July 15th, there was short interest totaling 496,200 shares, an increase of 70.7% from the June 30th total of 290,700 shares. Based on an average daily volume of 200 shares, the short-interest ratio is currently 2,481.0 days.
View Ono Pharmaceutical's Short Interest
.

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLF stock can currently be purchased for approximately $27.76.

How much money does Ono Pharmaceutical make?

Ono Pharmaceutical (OTCMKTS:OPHLF) has a market capitalization of $14.27 billion and generates $3.22 billion in revenue each year. The company earns $716.61 million in net income (profit) each year or $1.44 on an earnings per share basis.

How many employees does Ono Pharmaceutical have?

The company employs 3,687 workers across the globe.

How can I contact Ono Pharmaceutical?

Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The official website for the company is www.ono.co.jp. The company can be reached via phone at (166) 263-5670 or via fax at 816-6263-2950.

This page (OTCMKTS:OPHLF) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.